» Articles » PMID: 35692496

Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer

Overview
Journal J Immunol Res
Publisher Wiley
Date 2022 Jun 13
PMID 35692496
Authors
Affiliations
Soon will be listed here.
Abstract

This study is aimed at exploring the potential mechanism of the PPAR signaling pathway in breast cancer (BRCA) and constructing a novel prognostic-related risk model. We used various bioinformatics methods and databases to complete our exploration in this research. Based on TCGA database, we use multiple extension packages based on the R language for data conversion, processing, and statistics. We use LASSO regression analysis to establish a prognostic-related risk model in BRCA. And we combined the data of multiple online websites, including GEPIA, ImmuCellAI, TIMER, GDSC, and the Human Protein Atlas database to conduct a more in-depth exploration of the risk model. Based on the mRNA data in TCGA database, we conducted a preliminary screening of genes related to the PPAR signaling pathway through univariate Cox analysis, then used LASSO regression analysis to conduct a second screening, and successfully established a risk model consisting of ten genes in BRCA. The results of ROC curve analysis show that the risk model has good prediction accuracy. We can successfully divide breast cancer patients into high- and low-risk groups with significant prognostic differences ( = 1.92 - 05) based on this risk model. Combined with the clinical data in TCGA database, there is a correlation between the risk model and the patient's N, T, gender, and fustat. The results of multivariate Cox regression show that the risk score of this risk model can be used as an independent risk factor for BRCA patients. In particular, we draw a nomogram that can predict the 5-, 7-, and 10-year survival rates of BRCA patients. Subsequently, we conducted a series of pancancer analyses of CNV, SNV, OS, methylation, and immune infiltration for this risk model gene and used GDSC data to investigate drug sensitivity. Finally, to gain insight into the predictive value and protein expression of these risk model genes in breast cancer, we used GEO and HPA databases for validation. This study provides valuable clues for future research on the PPAR signaling pathway in BRCA.

Citing Articles

Development of a promising PPAR signaling pathway-related prognostic prediction model for hepatocellular carcinoma.

Shi Q, Zeng Y, Xue C, Chu Q, Yuan X, Li L Sci Rep. 2024; 14(1):4926.

PMID: 38418897 PMC: 10902383. DOI: 10.1038/s41598-024-55086-6.


TREM1 is involved in the mechanism between asthma and lung cancer by regulating the Toll‑like receptor signaling pathway.

Yan Z, Zhang W, Sun K Oncol Lett. 2023; 27(1):16.

PMID: 38028174 PMC: 10664071. DOI: 10.3892/ol.2023.14149.


Mdwgan-gp: data augmentation for gene expression data based on multiple discriminator WGAN-GP.

Li R, Wu J, Li G, Liu J, Xuan J, Zhu Q BMC Bioinformatics. 2023; 24(1):427.

PMID: 37957576 PMC: 10644641. DOI: 10.1186/s12859-023-05558-9.


Screening of novel biomarkers for breast cancer based on WGCNA and multiple machine learning algorithms.

Jin X, Huang Z, Guo P, Yuan R Transl Cancer Res. 2023; 12(6):1466-1489.

PMID: 37434679 PMC: 10331707. DOI: 10.21037/tcr-23-3.


Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer.

Xu Y, Shen M, Peng Y, Liu L, Tang L, Yang T Biomed Res Int. 2022; 2022:4632453.

PMID: 36082153 PMC: 9448600. DOI: 10.1155/2022/4632453.


References
1.
Dheeraj A, Agarwal C, Schlaepfer I, Raben D, Singh R, Agarwal R . A novel approach to target hypoxic cancer cells via combining β-oxidation inhibitor etomoxir with radiation. Hypoxia (Auckl). 2018; 6:23-33. PMC: 6109663. DOI: 10.2147/HP.S163115. View

2.
Flaig T, Salzmann-Sullivan M, Su L, Zhang Z, Joshi M, Gijon M . Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. Oncotarget. 2017; 8(34):56051-56065. PMC: 5593544. DOI: 10.18632/oncotarget.17359. View

3.
Torre L, Siegel R, Ward E, Jemal A . Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):16-27. DOI: 10.1158/1055-9965.EPI-15-0578. View

4.
Moresco M, Raccosta L, Corna G, Maggioni D, Soncini M, Bicciato S . Enzymatic Inactivation of Oxysterols in Breast Tumor Cells Constraints Metastasis Formation by Reprogramming the Metastatic Lung Microenvironment. Front Immunol. 2018; 9:2251. PMC: 6176086. DOI: 10.3389/fimmu.2018.02251. View

5.
Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H . Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res. 2018; 10:5329-5338. PMC: 6225920. DOI: 10.2147/CMAR.S176763. View